Latest News about REGN
Recent news which mentions REGN
From Benzinga
U.S. reopens to vaccinated travelers from 33 countries after 18 months, as global tally of COVID-19 cases tops 250 million
November 08, 2021
Tickers
REGN
Tags
REGN
From MarketWatch
From Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
From Benzinga
From Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
November 05, 2021
Tickers
REGN
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
November 05, 2021
From Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
From Benzinga
3 Reasons Why Investors Should Love Regeneron's Q3 Update
November 05, 2021
Tickers
REGN
From Motley Fool
Regeneron Pharmaceuticals Inc (REGN) Q3 2021 Earnings Call Transcript
November 04, 2021
Tickers
REGN
From Motley Fool
7 European Stocks to Buy to Diversify Your Portfolio
November 04, 2021
From InvestorPlace
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
From Benzinga
Is There Any Hope for Atea Pharmaceuticals Stock?
November 04, 2021
From Motley Fool
Healthcare Stocks Subject to Government Policy
November 02, 2021
From Benzinga
A Pfizer Drug Moves Closer to Approval in Another Important Indication
November 02, 2021
From Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
From Benzinga
Will Regeneron Be Worth More Than Amazon by 2030?
October 28, 2021
From Motley Fool
1 Small-Cap Stock With 10X Potential
October 27, 2021
From Motley Fool
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
From Benzinga
From Motley Fool
From Benzinga
Biotech Buyouts That Would Be Great for Investors
October 22, 2021
From Motley Fool
Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?
October 22, 2021
From Motley Fool
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free
Information
Copyright 2024. BUSINESS INSURANCE HOLDINGS
